Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Fig. 1

Schematic study overview. Figure shows the workflow of the INFORM Registry molecular pipeline followed by the respective phase I and phase II of the INFORM2 NivEnt trial. WES, whole exome sequencing; LC-WGS, low coverage whole genome sequencing; RNA-Seq, RNA sequencing. a Or equivalently valid molecular pipelines

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us